NASDAQ:CTIC - CTI BioPharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.38
  • Forecasted Upside: 257.91 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.34
▲ +0.01 (0.43%)

This chart shows the closing price for CTIC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CTI BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTIC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTIC

Analyst Price Target is $8.38
▲ +257.91% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for CTI BioPharma in the last 3 months. The average price target is $8.38, with a high forecast of $15.00 and a low forecast of $5.50. The average price target represents a 257.91% upside from the last price of $2.34.

This chart shows the closing price for CTIC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in CTI BioPharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/1/2021Lake Street CapitalBoost Price TargetBuy$13.00 ➝ $15.00High
5/6/2021Stifel NicolausInitiated CoverageBuy$5.50High
1/4/2021Lake Street CapitalBoost Price TargetBuy$8.00 ➝ $13.00N/A
10/23/2020Brookline Capital ManagementInitiated CoverageBuy$7.00Medium
9/30/2020Needham & Company LLCBoost Price TargetBuy$3.50 ➝ $6.00Low
7/5/2020Lake Street CapitalReiterated RatingBuy ➝ Market Perform$4.00Medium
6/24/2020JMP SecuritiesInitiated CoverageOutperform$3.00Low
4/27/2020Needham & Company LLCInitiated CoverageBuy$3.50High
2/3/2020Needham & Company LLCReiterated RatingBuy$3.50High
12/10/2019Needham & Company LLCReiterated RatingBuy$4.00High
11/5/2019Needham & Company LLCReiterated RatingBuy$4.00Low
3/5/2019Lake Street CapitalInitiated CoverageBuy$4.00Low
12/28/2018OppenheimerSet Price TargetBuy$4.00High
11/2/2018OppenheimerSet Price TargetBuy$4.00Medium
7/20/2018Jefferies Financial GroupReiterated RatingBuy$4.00Medium
7/10/2018JMP SecuritiesSet Price TargetBuy$8.00Low
3/26/2018Needham & Company LLCInitiated CoverageBuy ➝ Buy$10.00High
3/7/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$8.00Low
2/23/2018OppenheimerInitiated CoverageOutperform$5.00 ➝ $5.00High
9/12/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$7.50High
8/29/2016Piper Jaffray CompaniesReiterated RatingNeutral$7.50N/A
(Data available from 6/24/2016 forward)
CTI BioPharma logo
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $2.34
Low: $2.30
High: $2.41

50 Day Range

MA: $2.37
Low: $2.16
High: $2.54

52 Week Range

Now: $2.34
Low: $0.96
High: $4.13

Volume

401,085 shs

Average Volume

856,402 shs

Market Capitalization

$218.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73

Frequently Asked Questions

What sell-side analysts currently cover shares of CTI BioPharma?

The following Wall Street analysts have issued research reports on CTI BioPharma in the last twelve months: Brookline Capital Management, JMP Securities, Lake Street Capital, Needham & Company LLC, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for CTIC.

What is the current price target for CTI BioPharma?

4 Wall Street analysts have set twelve-month price targets for CTI BioPharma in the last year. Their average twelve-month price target is $8.38, suggesting a possible upside of 257.9%. Lake Street Capital has the highest price target set, predicting CTIC will reach $15.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $5.50 for CTI BioPharma in the next year.
View the latest price targets for CTIC.

What is the current consensus analyst rating for CTI BioPharma?

CTI BioPharma currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CTIC will outperform the market and that investors should add to their positions of CTI BioPharma.
View the latest ratings for CTIC.

What other companies compete with CTI BioPharma?

How do I contact CTI BioPharma's investor relations team?

CTI BioPharma's physical mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company's listed phone number is 206-282-7100 and its investor relations email address is [email protected] The official website for CTI BioPharma is www.ctibiopharma.com.